Dosimetry of 90Y-Ibritumomab Tiuxetan as Consolidation of First Remission in Advanced-Stage Follicular Lymphoma: Results from the International Phase 3 First-Line Indolent Trial

The objective of this analysis was to assess the radiation expo-sure associated with 90Y-ibritumomab tiuxetan when used as consolidation therapy in adults with low or minimal tumor burden after first-line therapy of advanced follicular lymphoma (FL). Methods: The patients who were enrolled in the phase 3 first-line indolent trial were 18 y or older, with CD201 grade 1 or 2 stage III or IV FL, and a partial response, complete response, or unconfirmed complete response to first-line chemotherapy. The patients were allocated randomly to receive a single infusion of unlabeled rituximab 250 mg/m2 on day 27 and consolidation on day 0 with a single dose of 90Y-ibritumomab tiuxetan, 14.8 MBq/kg, immediately after unlabeled rituximab, 250 mg/m2, or no further treatment. On day 27, a subset of patients received an injection of 185 MBq of 111In-ibritumomab tiuxetan immedi-ately after unlabeled rituximab, 250 mg/m2, for central dosimetr